公开(公告)号：US09937252B2

公开(公告)日：2018-04-10

申请号：US14766268

申请日：2014-02-06

申请人： SANOFI PASTEUR ,  IMPERIAL INNOVATIONS LIMITED

发明人： Gary McLean ,  Walton Ross ,  Sebastian Johnston ,  Nathan Wylie Bartlett ,  Bruno Guy ,  Yves Girerd-Chambaz ,  Valerie Lecouturier ,  Jeffrey Almond ,  Nicholas Glanville ,  Nicolas Burdin

IPC分类号： A61K39/125 ,  C07K14/005 ,  C12N9/12 ,  A61K39/12 ,  A61K39/00

CPC分类号： A61K39/125 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/005 ,  C07K2319/00 ,  C12N9/127 ,  C12N2770/32722 ,  C12N2770/32734

摘要： The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.

公开(公告)号：US20160095916A1

公开(公告)日：2016-04-07

申请号：US14766268

申请日：2014-02-06

申请人： SANOFI PASTEUR ,  IMPERIAL INNOVATIONS LIMITED

发明人： Gary McLean ,  Walton Ross ,  Sebastian Johnson ,  Nathan Bartlett ,  Bruno Guy ,  Yves Girerd-Chambaz ,  Valerie Lecouturier ,  Jeffrey Almond ,  Nicholas Glanville ,  Nicolas Burdin

IPC分类号： A61K39/125

CPC分类号： A61K39/125 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/005 ,  C07K2319/00 ,  C12N9/127 ,  C12N2770/32722 ,  C12N2770/32734

摘要： The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.

摘要翻译： 本发明涉及：a）分离的肽，其包含与鼻病毒的VP4氨基酸序列至少90％相同的氨基酸序列，或包含编码所述肽的核酸序列的分离的多核苷酸，其置于 其在哺乳动物细胞中表达所必需的元素; 和/或b）分离的肽，其包含至少100个氨基酸的氨基酸序列，其与位于鼻病毒RNA聚合酶的最后363个C末端氨基酸中的氨基酸序列至少90％相同，或 分离的多核苷酸，其包含编码所述肽的核酸序列，置于其在哺乳动物细胞中表达所必需的元件的控制下; 和c）当所述免疫原性组合物包含一种或多种所述分离的肽时，Th1佐剂。